Meeting
2020 ASCO Virtual Scientific Program
Long-term follow-up of anti-CD19 CAR T-cell therapy for B-cell lymphoma and chronic lymphocytic leukemia.
Authors
Kathryn Cappell
National Institute of Health, Bethesda, MD
Kathryn Cappell , Richard Mark Sherry , James C. Yang , Stephanie L. Goff , Danielle Vanasse , Lori McIntyre , Steven A. Rosenberg , James N. Kochenderfer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT00924326
Citation
J Clin Oncol 38: 2020 (suppl; abstr 3012)
DOI
10.1200/JCO.2020.38.15_suppl.3012
Abstract #
3012
Poster Bd #
76
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Prognostic role of lymphocyte to monocyte ratio in patients treated with CAR-T for aggressive lymphoma.
First Author: Henan Zhang
Poster
2018 ASCO Annual Meeting
ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL).
First Author: Olalekan O. Oluwole
Poster
2018 ASCO Annual Meeting
Clinical anti-lymphoma activity and toxicity of T cells expressing a novel anti-CD19 chimeric antigen receptor with fully-human variable regions.
First Author: Jennifer N. Brudno
Poster
2018 ASCO Annual Meeting
ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma.
First Author: Michael Wang